本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Akari Therapeutics PLC

1.38
-0.0200-1.43%
盘后1.35-0.0300-2.17%16:05 EDT
成交量:8,068.00
成交额:1.10万
市值:3,984.96万
市盈率:-0.56
高:1.39
开:1.28
低:1.28
收:1.40
数据加载中...
2024/03/05

企业合并公告

Form 425 - Prospectuses and communications, business combinations
2024/03/05

重要事件披露

Form 8-K - Current report
2024/01/05

超过5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2024/01/03

重要事件披露

Form 8-K - Current report
2023/10/25

SEC问询函

Form CORRESP - Correspondence
2023/10/20

超过5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2023/10/13

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2023/05/31

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2023/05/01

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2023/04/14

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2023/02/14

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2022/11/07

SEC问询函

CORRESP [Cover] - Correspondence
2022/11/04

[修订]招股说明书

F-1/A [Amend] - Registration statement for certain foreign private issuers
2022/10/12

招股说明书

F-1 - Registration statement for certain foreign private issuers
2022/05/16

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2022/02/14

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2022/01/14

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2021/08/30

SEC问询函

CORRESP [Cover] - Correspondence
2021/04/21

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2021/02/16

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals